SecBot SecBot
SECBOTREPLAY Home › Report › CHRS

CHRS · Coherus Oncology reported strong revenue growth for LOQTORZI, with…

Coherus Oncology, Inc. · PRESS-RELEASE filed Mar 9, 2026 at 16:15 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 9, 2026 at 16:15 ET

Coherus Oncology reported strong revenue growth for LOQTORZI, with full-year 2025 net revenue reaching $42.2 million, up 60% YoY, driven by increasing patient demand and treatment duration. The company significantly reduced its debt by 90% to $38.8 million and bolstered its cash position to $172.1 million through equity financings, while advancing a promising oncology pipeline with multiple 2026 clinical readouts expected.

  • LOQTORZI net revenue grew 60% YoY to $42.2 million in 2025, up from $26.4 million in 2024
  • Q4 2025 LOQTORZI revenue was $12.4 million, up 64% YoY and 11% QoQ
  • Debt reduced from $480 million peak to $38.8 million by end of 2025
  • Cash, cash equivalents, and marketable securities totaled $172.1 million as of December 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access